Daehan New Pharm Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 4.14%

Daehan New Pharm Co. Ltd (054670) has an Asset Resilience Ratio of 4.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Daehan New Pharm Co. Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩10.40 Billion
≈ $7.05 Million USD Cash + Short-term Investments

Total Assets

₩251.53 Billion
≈ $170.46 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Daehan New Pharm Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 054670 total asset value.

Liquid Assets Composition Over Time

This chart breaks down Daehan New Pharm Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Daehan New Pharm Co. Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩10.40 Billion 4.14%
Total Liquid Assets ₩10.40 Billion 4.14%

Asset Resilience Insights

  • Limited Liquidity: Daehan New Pharm Co. Ltd maintains only 4.14% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Daehan New Pharm Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Daehan New Pharm Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.48%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
Drug Manufacturers - Specialty & Generic 1.01%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Drug Manufacturers - Specialty & Generic 5.90%

Annual Asset Resilience Ratio for Daehan New Pharm Co. Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Daehan New Pharm Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 16.58% ₩36.70 Billion
≈ $24.87 Million
₩221.29 Billion
≈ $149.96 Million
+3.61pp
2023-12-31 12.98% ₩22.96 Billion
≈ $15.56 Million
₩176.93 Billion
≈ $119.90 Million
-3.88pp
2022-12-31 16.86% ₩28.55 Billion
≈ $19.35 Million
₩169.36 Billion
≈ $114.77 Million
+3.22pp
2021-12-31 13.63% ₩21.49 Billion
≈ $14.57 Million
₩157.64 Billion
≈ $106.83 Million
-1.66pp
2020-12-31 15.30% ₩20.36 Billion
≈ $13.80 Million
₩133.08 Billion
≈ $90.18 Million
+1.83pp
2019-12-31 13.47% ₩17.23 Billion
≈ $11.67 Million
₩127.91 Billion
≈ $86.68 Million
+5.95pp
2018-12-31 7.51% ₩8.17 Billion
≈ $5.54 Million
₩108.74 Billion
≈ $73.69 Million
+2.69pp
2017-12-31 4.83% ₩5.88 Billion
≈ $3.98 Million
₩121.82 Billion
≈ $82.55 Million
-2.97pp
2016-12-31 7.80% ₩10.19 Billion
≈ $6.91 Million
₩130.72 Billion
≈ $88.59 Million
+7.18pp
2015-12-31 0.61% ₩812.31 Million
≈ $550.49K
₩132.63 Billion
≈ $89.88 Million
-0.24pp
2014-12-31 0.86% ₩1.12 Billion
≈ $757.86K
₩130.47 Billion
≈ $88.42 Million
--
pp = percentage points

About Daehan New Pharm Co. Ltd

KQ:054670 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$52.98 Million
₩78.18 Billion KRW
Market Cap Rank
#21781 Global
#1307 in Korea
Share Price
₩5570.00
Change (1 day)
+0.00%
52-Week Range
₩5090.00 - ₩7510.00
All Time High
₩21012.38
About

Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormo… Read more